Secondary malignancy in patients with sporadic neuroendocrine neoplasia

被引:9
作者
Krausch, M. [1 ]
Raffel, A. [1 ]
Anlauf, M. [2 ]
Schott, M. [3 ]
Lehwald, N. [1 ]
Krieg, A. [1 ]
Kroepil, F. [1 ]
Cupisti, K. [1 ]
Knoefel, W. T. [1 ]
机构
[1] Univ Dusseldorf, Dept Gen Visceral & Pediat Surg, D-40225 Dusseldorf, Germany
[2] Univ Dusseldorf, Inst Pathol, D-40225 Dusseldorf, Germany
[3] Univ Dusseldorf, Dept Endocrinol Diabet & Rheumatol, D-40225 Dusseldorf, Germany
关键词
Secondary malignancy; Neuroendocrine neoplasia; Tumor incidence; 2ND PRIMARY MALIGNANCY; PROGNOSTIC-FACTORS; COLORECTAL-CANCER; GROWTH-FACTORS; TUMORS; GASTRIN; EXPRESSION; MANAGEMENT; RISK; RECEPTORS;
D O I
10.1007/s12020-013-9911-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The incidence of neuroendocrine neoplasias (NENs), especially of the gastro-entero-pancreatic (GEP), system relatively increased over the past decades, as a result of advanced diagnostic tools, a better clinical awareness, and distinguished pathological diagnostic recognition. Previous reports hypothesized an increased risk for secondary malignancies in patients with NEN especially in GEP-NENs. The present study was designed to investigate the coincidence of NENs and secondary malignancies in a large patient collective. A retrospective analysis was performed on 161 patients (85 female and 76 male) with NEN of various origins. Clinical data of these patients, different classification systems (TNM/WHO), proliferations-based grading, and clinical follow-up were collected and analyzed. Out of 143 patients with a sporadic NEN, 15 (10.49 %) patients were identified with secondary malignant tumors. Median age at the time of the primary operation for NEN was 65 years, whereas the median age of initial diagnosis of associated tumors was 59 years. Mean follow-up time was 61 months. The risk of developing a secondary malignancy was most elevated for patients with an NEN of the lung, the stomach, and the ileum (60, 50 and 20 %, respectively). The spectrum of secondary malignancies included various types of cancer. Kaplan-Meier survival analysis shows a difference suggesting that patients with a secondary malignancy demonstrate a worse survival compared to patients without a secondary tumor; no significance was detected (p = 0.349). Our data suggest that secondary malignancies in patients with NEN's especially in GEP-NENs are found more frequently than in general population. Therefore, patients with NEN need a continuous and detailed follow-up. The reason for the increased incidence of secondary malignancies in patients with NENs remains to be elucidated.
引用
收藏
页码:510 / 516
页数:7
相关论文
共 56 条
[1]   Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy [J].
Alexandraki, Krystallenia I. ;
Kaltsas, Gregory .
ENDOCRINE, 2012, 41 (01) :40-52
[2]  
Anlauf M, 2011, CHIRURG, V82, P567, DOI 10.1007/s00104-011-2067-y
[3]   Hereditary neuroendocrine tumors of the gastroenteropancreatic system [J].
Anlauf, Martin ;
Garbrecht, Nele ;
Bauersfeld, Juliane ;
Schmitt, Anja ;
Henopp, Tobias ;
Komminoth, Paul ;
Heitz, Philipp U. ;
Perren, Aurel ;
Kloeppel, Guenter .
VIRCHOWS ARCHIV, 2007, 451 :S29-S38
[4]  
[Anonymous], 2010, WHO Classification of tumors of the digestive system
[5]   GASTRIN STIMULATES GROWTH OF HUMAN COLON-CANCER CELLS VIA A RECEPTOR OTHER THAN CCK-A OR CCK-B [J].
BOLD, RJ ;
ISHIZUKA, J ;
TOWNSEND, CM ;
THOMPSON, JC .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 202 (03) :1222-1226
[6]  
Bold RJ, 1998, ANTICANCER RES, V18, P4051
[7]  
Brune M, 2003, DEUT MED WOCHENSCHR, V128, P2413
[8]  
CHAUDHRY A, 1994, ANTICANCER RES, V14, P2085
[9]   Management of Neuroendocrine Tumors: A Meeting of Experts from Latin America [J].
Costa, F. ;
Domenichini, E. ;
Garavito, G. ;
Medrano, R. ;
Mendez, G. ;
O'Connor, J. ;
Rojas, W. ;
Torres, S. ;
Younes, R. N. ;
Delle Fave, G. ;
Oberg, K. .
NEUROENDOCRINOLOGY, 2008, 88 (03) :235-242
[10]   Secondary cancers after a lung carcinoid primary: A population-based analysis [J].
Cote, M. L. ;
Wenzlaff, A. S. ;
Philip, P. A. ;
Schwartz, A. G. .
LUNG CANCER, 2006, 52 (03) :273-279